March 8 (Reuters) - Johnson & Johnson's prostate cancer drug Zytiga improved survival in patients who have not received chemotherapy in a late-stage study.
An independent data monitoring committee recommended that patients receiving a placebo in the trial be offered treatment with Zytiga, the company said in a statement.
Thursday's data sent shares of Medivation Inc, which is also developing a prostate cancer pill that works by targeting the same hormone that Zytiga targets, up 9 percent.
However, shares of Dendreon Corp fell 16 percent. Dendreon makes a prostate cancer vaccine, Provenge, that has a different mechanism of action.
(Reporting by Kavyanjali Kaushik and Esha Dey in Bangalore; Editing by Gopakumar Warrier) Keywords: JOHNSONANDJOHNSON/
(kavyanjali.kaushik@thomsonreuters.com; within U.S. +1 646 223 8780; outside U.S. +91 80 4135 5800; Reuters Messaging: kavyanjali.kaushik.thomsonsonreuters.com@reuters.net)
COPYRIGHT
Copyright Thomson Reuters 2012. All rights reserved.
The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.
jon bon jovi jon bon jovi kim jong il died warren hellman survivor south pacific survivor south pacific house of wax
No comments:
Post a Comment